Abiomed's Impella® Technology that Enables Heart Recovery Showcased at TCT 2017 With More Than 30 Presentations
October 19 2017 - 4:00PM
Abiomed Inc. (NASDAQ:ABMD), a leading provider of
breakthrough heart support and recovery technologies, announces
that there are more than 30 presentations potentially featuring the
Impella® line of heart pumps scheduled during the 29th
Transcatheter Cardiovascular Therapeutics (TCT) conference, the
annual scientific symposium of the Cardiovascular Research
Foundation, being held October 29 - November 2, at the Colorado
Convention Center in Denver, CO.
Impella® heart pumps are enabling heart recovery
for the growing population of undertreated advanced coronary artery
disease patients that may benefit from complete revascularization.
Abiomed is committed to advancing the science of heart recovery
through technology and innovation, education and clinical research.
The following initiatives are planned for TCT:
- Abiomed Booth Activities Abiomed's booth #1012
will feature clinical data, demonstrations and opportunities for
physicians to engage in hands-on simulations of the Impella
platform. Abiomed is debuting a new simulation tool that allows
physicians to experience the use of hemodynamic support with the
left-sided Impella CP® and the Impella RP® heart pump, which
recently received pre-market approval from the U.S. Food and Drug
Administration for support of the right side of the heart. This is
a unique training tool for insertion, placement and management of
the Impella platform.
- ProtectedPCI.com Digital Community Abiomed's
digital community is the largest source of educational resources on
the Impella platform of devices. Materials available include
protocols and algorithms for appropriate use, summaries on the
latest clinical publications and studies, case recordings and
updates from TCT 2017. Learn more and sign up for updates at
www.protectedpci.com.
- Potential Live Cases Utilizing Impella Devices
Abiomed anticipates the potential broadcast of several elective
live cases utilizing Impella devices from participating sites in
the main arena, coronary theater, and structural heart theater in
the Colorado Convention Center. Further details regarding these
live cases will be announced the day of the scheduled procedures as
patient status is subject to change.
- Investor EventAbiomed will host an investor
event on Monday, October 30, from 3:15 – 4:15 p.m. To request
attendance, please email ir@abiomed.com.
The schedule for Protected PCI and cardiogenic shock-related TCT
symposia is included below. Additional Impella device-related
presentations and poster sessions are anticipated.
MONDAY, OCTOBER 30
Breakfast Program: TCT Cardiogenic Shock Initiative
(TCT-CSI) Colorado Convention Center, 506-507 7:00 — 8:00
a.m. Faculty:
William O'Neill, MD; Medical Director, Center for Structural
Health Disease, Henry Ford Hospital Navin Kapur, MD; Director,
Acute Circulatory Support Programs, Tufts Medical Center
TUESDAY, OCTOBER 31
Breakfast Program: Management of Complex PCI Patients –
Award-Winning Case Presentations Colorado Convention
Center, 502 7:00 — 8:00 a.m.
Evening Program: The Interventional Toolbox for Complex
Higher-Risk (and Indicated) Patients (CHIP) Hyatt Regency
Denver, Centennial Ballroom A-C 6:30 — 8:00 p.m.
WEDNESDAY, NOVEMBER 1
Presentation Theater Program: Contrast-Induced Acute
Kidney Injury – Preventive Measures That Work Colorado
Convention Center, Presentation Theater 5 11:30 a.m. — 12:30
p.m.
ABOUT IMPELLA HEART PUMPS
The Impella 2.5®, Impella CP® and Impella 5.0®
are FDA-approved heart pumps used to treat heart attack patients in
cardiogenic shock, and have the unique ability to enable native
heart recovery, allowing patients to return home with their own
heart. The Impella 2.5 and Impella CP devices are also approved to
treat certain advanced heart failure patients undergoing elective
and urgent percutaneous coronary interventions (PCI) such as
stenting or balloon angioplasty, to re-open blocked coronary
arteries. Abiomed's right-side heart pump, the Impella RP® device,
is FDA approved to treat patients experiencing acute right heart
failure or decompensation following left ventricular assist
device implantation, myocardial infarction, heart transplant,
or open-heart surgery. To learn more about the Impella platform of
heart pumps, including their approved indications and important
safety and risk information associated with the use of the devices,
please visit: www.protectedpci.com.
The ABIOMED logo, ABIOMED, Impella, Impella 2.5, Impella 5.0,
Impella LD, Impella CP, Impella RP, and Recovering Hearts. Saving
Lives. are registered trademarks of ABIOMED, Inc. in the U.S. and
in certain foreign countries.
ABOUT ABIOMED Based in
Danvers, Massachusetts, Abiomed, Inc. is a leading provider of
medical devices that provide circulatory support. Our products
are designed to enable the heart to rest by improving blood flow
and/or performing the pumping of the heart. For additional
information, please visit: www.abiomed.com.
**For further information please contact:
Ingrid Goldberg WardDirector, Investor
Relations978-646-1590igoldberg@abiomed.com
FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, including
statements regarding development of Abiomed's existing and new
products, the Company's progress toward commercial growth, and
future opportunities and expected regulatory approvals. The
Company's actual results may differ materially from those
anticipated in these forward-looking statements based upon a number
of factors, including uncertainties associated with development,
testing and related regulatory approvals, including the potential
for future losses, complex manufacturing, high quality
requirements, dependence on limited sources of supply, competition,
technological change, government regulation, litigation matters,
future capital needs and uncertainty of additional financing, and
other risks and challenges detailed in the Company's filings with
the Securities and Exchange Commission, including the most recently
filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
Readers are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date of this
release. The Company undertakes no obligation to publicly release
the results of any revisions to these forward-looking statements
that may be made to reflect events or circumstances that occur
after the date of this release or to reflect the occurrence of
unanticipated events.
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Apr 2024 to May 2024
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From May 2023 to May 2024